Of the Rs 700 crore, a sum of Rs 243 crore has been approved for 2024-25, according to a notification issued by the Department of Pharmaceuticals (DoP), under the Ministry of Chemicals and Fertilizers.
Currently there are seven NIPERs covering seven states of the country (Punjab), Ahmedabad (Gujarat), Hajipur (Bihar), Hyderabad (Telangana), Kolkata (West Bengal), Guwahati (Assam) and Rae Bareli (Uttar Pradesh).
These will broadly focus on research ranging from medical device manufacturing, bulk drug research and development, phytopharmaceuticals, biological therapeutics, and antiviral and antibacterial drug discovery and development.
Former health minister Mansukh Mandaviya said that the Union Cabinet in 2023 approved the Promotion of Research and Innovation in Pharma-MedTech (PRIP) scheme with an outlay of Rs 5,000 crore over five years from 2023- 24 to 2027-28.
Again in 2023, a parliamentary panel recommended that the government allocate more funds for new initiatives such as the establishment of the National Institute of Medical Devices Education and Research (NIMER) and the Indian Council of Research, Development and Innovation in Pharma-MedTech Sector (ICPMR). ).
It was mentioned that the DoP had requested Rs 1,286 crore for FY24, of which Rs 560 crore was earmarked for establishing NIPER, and the remaining amount will be used for new initiatives under the NIPER scheme such as NIMER (200 crores). ), Centers of Excellence (Rs. 233 million), ICPMR (Rs. 50 million) and Promotion of Research and Innovation in Pharmaceutical Sector (Rs. 243.00 million).
Meanwhile, according to media reports, a production-linked incentive (PLI) scheme for domestic production of glucagon-like peptide 1 (GLP-1) drugs by 2026.
It is important for the Indian population, with a rising incidence of diabetes and obesity. The current formulations of GLP-1 drugs from US companies Novo Nordisk (Ozempic) and Eli Lilly (Zepbound) are not available in India.
Currently there are seven NIPERs covering seven states of the country (Punjab), Ahmedabad (Gujarat), Hajipur (Bihar), Hyderabad (Telangana), Kolkata (West Bengal), Guwahati (Assam) and Rae Bareli (Uttar Pradesh).
These will broadly focus on research ranging from medical device manufacturing, bulk drug research and development, phytopharmaceuticals, biological therapeutics, and antiviral and antibacterial drug discovery and development.
Former health minister Mansukh Mandaviya said that the Union Cabinet in 2023 approved the Promotion of Research and Innovation in Pharma-MedTech (PRIP) scheme with an outlay of Rs 5,000 crore over five years from 2023- 24 to 2027-28.
Again in 2023, a parliamentary panel recommended that the government allocate more funds for new initiatives such as the establishment of the National Institute of Medical Devices Education and Research (NIMER) and the Indian Council of Research, Development and Innovation in Pharma-MedTech Sector (ICPMR). ).
It was mentioned that the DoP had requested Rs 1,286 crore for FY24, of which Rs 560 crore was earmarked for establishing NIPER, and the remaining amount will be used for new initiatives under the NIPER scheme such as NIMER (200 crores). ), Centers of Excellence (Rs. 233 million), ICPMR (Rs. 50 million) and Promotion of Research and Innovation in Pharmaceutical Sector (Rs. 243.00 million).
Meanwhile, according to media reports, a production-linked incentive (PLI) scheme for domestic production of glucagon-like peptide 1 (GLP-1) drugs by 2026.
It is important for the Indian population, with a rising incidence of diabetes and obesity. The current formulations of GLP-1 drugs from US companies Novo Nordisk (Ozempic) and Eli Lilly (Zepbound) are not available in India.
